Novartis AG (ADR) (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the use of RLX030 (serelaxin) in the treatment of acute heart failure (AHF) indicating that further evidence is required for a license to be granted in the EU. Novartis AG (ADR) (NYSE:NVS) net profit margin is 16.50% and weekly performance is 0.37%. On last trading day company shares ended up $90.21. Analysts mean target price for the company is $87.94. Novartis AG (ADR) (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 5.95%.
Lonza Group AG (OTCMKTS:LZAGY) announced on 28 April changes in the composition of Lonza’s Executive Committee (EC) to ensure continuity and focused delivery of the Pharma&Biotech growth strategy. LONZA GROUP AG (OTCMKTS:LZAGY) shares advanced 1.33% in last trading session and ended the day on $10.66
Oncomed Pharmaceuticals (NASDAQ:OMED) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a note issued to investors on Tuesday, Stock Ratings Network.com reports. The firm currently has a $23.10 price target on the stock. Zacks‘s price target points to a potential upside of 2.53% from the stock’s previous close. Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) shares moved up 2.39% in last trading session and was closed at $22.30, while trading in range of $21.31 – $22.96. Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) year to date (YTD) performance is -24.46%.
Johnson & Johnson (NYSE:JNJ), the world’s biggest health-care products company, is bolstering its medical device presence in China as some companies struggle with government rules in one of the world’s fastest growing markets. Johnson & Johnson (NYSE:JNJ) ended the last trading day at $100.98. Company weekly volatility is calculated as 0.78% and price to cash ratio as 9.78.Johnson & Johnson (NYSE:JNJ) showed a positive weekly performance of 1.10%.
In a move to broaden its presence in the Latin American market, Abbott Labs (NYSE:ABT) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. Abbott Laboratories (NYSE:ABT) net profit margin is 13.60% and weekly performance is 1.38%. On last trading day company shares ended up $39.60. Analysts mean target price for the company is $41.32. Abbott Laboratories (NYSE:ABT) distance from 50-day simple moving average (SMA50) is 2.61%.
Leave a Reply